

Perkins Discovery Fund
Schedule of Investments
December 31, 2024 (unaudited)

	<u>Shares</u>	<u>Value</u>
103.37% COMMON STOCK		
24.85% BIOTECHNOLOGY		
Elutia Inc. ^(A)	42,500	\$ 158,950
MDxHealth SA ^(A)	32,500	77,025
Veracyte, Inc. ^(A)	20,000	792,000
Vericel Corp. ^(A)	15,000	823,650
		<u>1,851,625</u>
5.86% CONSUMER DISCRETIONARY		
Magnite, Inc. ^(A)	20,000	318,400
Perion Network Ltd. ^(A)	14,000	118,580
		<u>436,980</u>
1.72% FINANCIALS		
FlexShopper, Inc. ^(A)	75,000	128,250
		<u>128,250</u>
9.57% HEALTH CARE DRUGS/SERVICES		
ANI Pharmaceuticals, Inc. ^(A)	6,350	351,028
NeoGenomics, Inc. ^(A)	22,000	362,560
		<u>713,588</u>
3.07% HEALTH CARE MANUFACTURING		
AtriCure, Inc. ^(A)	7,500	229,200
		<u>229,200</u>
16.86% HEALTH CARE SUPPLIES		
Axogen, Inc. ^(A)	32,500	535,600
BioLife Solutions, Inc. ^(A)	12,500	324,500
Exagen, Inc. ^(A)	16,500	67,650
Myomo, Inc. ^(A)	13,600	87,584
TELA Bio, Inc. ^(A)	80,000	241,600
		<u>1,256,934</u>
12.57% HEALTH CARE SUPPORT		
Natera, Inc. ^(A)	5,100	807,330
Option Care Health, Inc. ^(A)	4,000	92,800
Rockwell Medical, Inc. ^(A)	18,181	37,089
		<u>937,219</u>

Perkins Discovery Fund
Schedule of Investments
December 31, 2024 (unaudited)

	Shares	Value
2.85% HEALTH CARE TECHNOLOGY		
OptimizeRX Corp. ^(A)	14,000	\$ 68,040
Streamline Health Solutions, Inc. ^(A)	8,733	32,836
Tactile Systems Technology, Inc. ^(A)	6,500	111,345
		212,221
14.50% INFORMATION TECHNOLOGY		
Airgain, Inc. ^(A)	14,500	102,370
Cantaloupe, Inc. ^(A)	40,000	380,400
Digi International, Inc. ^(A)	10,000	302,300
Inuvo, Inc. ^(A)	457,500	295,728
		1,080,798
11.52% SOFTWARE SERVICES		
Asure Software, Inc. ^(A)	25,000	235,250
Backblaze, Inc.	30,000	180,600
ePlus, Inc. ^(A)	6,000	443,280
		859,130
103.37% TOTAL COMMON STOCK		7,705,945
3.26% MONEY MARKET FUND		
Fidelity Government Portfolio 4.38% ^(B)	243,160	243,160
106.63% TOTAL INVESTMENTS		7,949,105
(6.63%) Liabilities in excess of other assets		(494,396)
100.00% NET ASSETS		\$ 7,454,709

^(A)Non-income producing

^(B)Effective 7 day yield as of December 31, 2024

In accordance with U.S. GAAP, "fair value" is defined as the price that a Fund would receive upon selling an investment in an orderly transaction to an independent buyer in the principal or most advantageous market for the investment. Various inputs are used in determining the value of a Fund's investments. U.S. GAAP established a three-tier hierarchy of inputs to establish a classification of fair value measurements for disclosure purposes. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Level 3 includes significant unobservable inputs (including the Fund's own assumptions in determining fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following summarizes the inputs used to value the Fund's investments as of December 31, 2024:

	Level 1	Level 2	Level 3	
	Quoted Prices	Other Significant Observable Inputs	Significant Unobservable Inputs	Total
COMMON STOCK	\$ 7,705,945			\$ 7,705,945
MONEY MARKET FUND	\$ 243,160			\$ 243,160
TOTAL INVESTMENTS	\$ 7,949,105			\$ 7,949,105

The cost of investments for Federal income tax purposes has been estimated as of December 31, 2024 since the final tax characteristics cannot be determined until fiscal year end. Cost of securities for Federal income tax purpose is \$4,208,783, and the related net unrealized appreciation (depreciation) consists of:

Gross unrealized appreciation	\$ 4,739,307
Gross unrealized depreciation	(998,985)
Net unrealized appreciation	<u>\$ 3,740,322</u>